RA CAPITAL MANAGEMENT, L.P. - 27 Jul 2021 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
Director
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
CTKB
Transactions as of
27 Jul 2021
Net transactions value
+$50,150,000
Form type
4
Filing time
29 Jul 2021, 16:30:54 UTC
Previous filing
22 Jul 2021
Next filing
28 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTKB Common Stock Conversion of derivative security +5,150,751 5,150,751 27 Jul 2021 See footnotes F1, F2, F5
transaction CTKB Common Stock Purchase $46,967,362 +2,762,786 +54% $17.00 7,913,537 27 Jul 2021 See footnotes F2, F5
transaction CTKB Common Stock Conversion of derivative security +998,553 998,553 27 Jul 2021 See footnotes F1, F3, F5
transaction CTKB Common Stock Purchase $3,182,638 +187,214 +19% $17.00 1,185,767 27 Jul 2021 See footnotes F3, F5
transaction CTKB Common Stock Conversion of derivative security +507,724 507,724 27 Jul 2021 See footnotes F1, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTKB Series D Preferred Stock Conversion of derivative security $0 -5,150,751 -100% $0.000000* 0 27 Jul 2021 Common Stock 5,150,751 See footnotes F1, F2, F5
transaction CTKB Series D Preferred Stock Conversion of derivative security $0 -998,553 -100% $0.000000* 0 27 Jul 2021 Common Stock 998,553 See footnotes F1, F3, F5
transaction CTKB Series D Preferred Stock Conversion of derivative security $0 -507,724 -100% $0.000000* 0 27 Jul 2021 Common Stock 507,724 See footnotes F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 27, 2021, each share of Series D Preferred Stock (the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2 These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3 These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").
F4 These securities are held directly by a separately managed account (the "Account").
F5 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Remarks:

Theresa Cameron, a Principal of the Adviser, serves on the Issuer's board of directors.